Univariate and multivariate analysis of prognostic factors associated with relapse (PF2) and survival (OS2) of R/R MCL after brexu-cel failure
| Prognostic factors . | Univariate model . | MCL treated patients, N = 49 . | ||||
|---|---|---|---|---|---|---|
| Multivariate model∗ . | ||||||
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| PFS2 | ||||||
| Age at infusion | 0.990 | 0.958-1.023 | .5557 | |||
| Number of previous lines >2 | 0.657 | 0.306-1.407 | .2792 | |||
| Number of previous lines >3 | 0.896 | 0.451-1.776 | .7523 | |||
| Nonresponder to bridging | 1.866 | 0.930-3.745 | .0792 | |||
| Ann Arbor stage in class III-IV | 0.467 | 0.125-1.749 | .2587 | |||
| TP53 mutation | 1.206 | 0.556-2.617 | .6360 | |||
| Bulk disease | 0.818 | 0.401-1.667 | .5802 | |||
| High MIPI risk at infusion (≥6.2) | 4.025 | 1.307-12.395 | .0152 | 3.268 | 1.036-10.305 | .0433 |
| ECOG PS in class at infusion ≥2 | 1.306 | 0.585-2.912 | .5147 | |||
| LDH (IU/L) at infusion more than the upper limit | 1.015 | 0.499-2.066 | .9666 | |||
| POD24 | 0.442 | 0.156-1.256 | .1255 | |||
| Blastoid variant | 2.186 | 1.074-4.452 | .0311 | 2.199 | 1.010-4.791 | .0472 |
| CRS | 0.625 | 0.258-1.514 | .2979 | |||
| Neurotoxicity | 1.246 | 0.643-2.412 | .5146 | |||
| TCE salvage treatment vs others | 0.598 | 0.210-1.701 | .3351 | |||
| OS2 | ||||||
| Age at infusion | 1.003 | 0.965-1.043 | .8756 | |||
| Number of previous lines >2 | 0.872 | 0.369-2.058 | .7545 | |||
| Number of previous lines >3 | 0.942 | 0.446 -1.992 | .8766 | |||
| Not responder to bridging | 3.407 | 1.550-7.487 | .0023 | 3.576 | 1.472-8.686 | .0049 |
| Ann Arbor stage in class III-IV | 0.790 | 0.168-3.725 | .7663 | |||
| TP53 mutation | 1.438 | 0.625-3.307 | .3925 | |||
| Ki-67 (%) ≥30% | 3.111 | 0.898-10.780 | .0735 | |||
| POD24 | 0.382 | 0.115- 1.262 | .1144 | |||
| Bulky disease | 0.903 | 0.404-2.018 | .8039 | |||
| High MIPI risk at infusion (≥6.2) | 6.257 | 1.922-20.367 | .0023 | 4.095 | 1.207-13.897 | .0238 |
| ECOG in class at infusion ≥2 | 2.091 | 0.892-4.902 | .0897 | |||
| LDH (IU/L) at infusion > upper limit | 1.470 | 0.680-3.175 | .3274 | |||
| Blastoid variant | 1.598 | 0.730-3.499 | .2408 | |||
| CRS | 1.401 | 0.487-4.030 | .5320 | |||
| Neurotoxicity | 1.458 | 0.701-3.034 | .3134 | |||
| TCE salvage treatment vs others | 0.391 | 0.118-1.299 | .1253 | |||
| Prognostic factors . | Univariate model . | MCL treated patients, N = 49 . | ||||
|---|---|---|---|---|---|---|
| Multivariate model∗ . | ||||||
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| PFS2 | ||||||
| Age at infusion | 0.990 | 0.958-1.023 | .5557 | |||
| Number of previous lines >2 | 0.657 | 0.306-1.407 | .2792 | |||
| Number of previous lines >3 | 0.896 | 0.451-1.776 | .7523 | |||
| Nonresponder to bridging | 1.866 | 0.930-3.745 | .0792 | |||
| Ann Arbor stage in class III-IV | 0.467 | 0.125-1.749 | .2587 | |||
| TP53 mutation | 1.206 | 0.556-2.617 | .6360 | |||
| Bulk disease | 0.818 | 0.401-1.667 | .5802 | |||
| High MIPI risk at infusion (≥6.2) | 4.025 | 1.307-12.395 | .0152 | 3.268 | 1.036-10.305 | .0433 |
| ECOG PS in class at infusion ≥2 | 1.306 | 0.585-2.912 | .5147 | |||
| LDH (IU/L) at infusion more than the upper limit | 1.015 | 0.499-2.066 | .9666 | |||
| POD24 | 0.442 | 0.156-1.256 | .1255 | |||
| Blastoid variant | 2.186 | 1.074-4.452 | .0311 | 2.199 | 1.010-4.791 | .0472 |
| CRS | 0.625 | 0.258-1.514 | .2979 | |||
| Neurotoxicity | 1.246 | 0.643-2.412 | .5146 | |||
| TCE salvage treatment vs others | 0.598 | 0.210-1.701 | .3351 | |||
| OS2 | ||||||
| Age at infusion | 1.003 | 0.965-1.043 | .8756 | |||
| Number of previous lines >2 | 0.872 | 0.369-2.058 | .7545 | |||
| Number of previous lines >3 | 0.942 | 0.446 -1.992 | .8766 | |||
| Not responder to bridging | 3.407 | 1.550-7.487 | .0023 | 3.576 | 1.472-8.686 | .0049 |
| Ann Arbor stage in class III-IV | 0.790 | 0.168-3.725 | .7663 | |||
| TP53 mutation | 1.438 | 0.625-3.307 | .3925 | |||
| Ki-67 (%) ≥30% | 3.111 | 0.898-10.780 | .0735 | |||
| POD24 | 0.382 | 0.115- 1.262 | .1144 | |||
| Bulky disease | 0.903 | 0.404-2.018 | .8039 | |||
| High MIPI risk at infusion (≥6.2) | 6.257 | 1.922-20.367 | .0023 | 4.095 | 1.207-13.897 | .0238 |
| ECOG in class at infusion ≥2 | 2.091 | 0.892-4.902 | .0897 | |||
| LDH (IU/L) at infusion > upper limit | 1.470 | 0.680-3.175 | .3274 | |||
| Blastoid variant | 1.598 | 0.730-3.499 | .2408 | |||
| CRS | 1.401 | 0.487-4.030 | .5320 | |||
| Neurotoxicity | 1.458 | 0.701-3.034 | .3134 | |||
| TCE salvage treatment vs others | 0.391 | 0.118-1.299 | .1253 | |||
CRS, cytokine release syndrome; LDH, lactate dehydrogenase.
Multivariate analysis was performed on 42/49 for PFS and 44/49 patients with available data for OS.